Abstract
Among patients with cancer, many factors can cause severe and persistent neutropenia, leading to increased morbidity and mortality. For patients with neutrophil deficiency, replacement with granulocyte transfusion (GTX) seems a rational approach. However, existing data on the efficacy of GTX have been inconclusive, and such adverse effects as respiratory distress and death indicate the need for further investigation into its efficacy. The purpose of this literature review was to address the question, “Are granulocyte transfusions effective in the management of adult oncology patients with neutropenia?” The focus was on adequate dosing, optimal timing of initiation, and adverse effects. Implications for practice for the provider and the niche population of neutropenic adult oncology patients that might benefit from GTX are presented.
